WARSAW, 31 Jan (APM) - According to the Economist Intelligence Unit, Poland has the highest mortality rate and the highest disability adjusted life-years (DALY) factor from lung cancer of the European countries surveyed, despite 160 million zlotys (€37.4 million) worth of dedicated drug programmes, reports Rzeczpospolita (pQ3) on Tuesday.
The Ministry of Health (MoH) has announced the establishment of cancer units, specialist diagnosis and healthcare facilities dedicated to cancer patients and facilitating access to innovative treatment. The MoH also declared it would introduce the long-awaited innovative first-line immunotherapy drug programme for stage IV lung cancer patients in May this year. Its price is currently being negotiated with the Economic Commission.
Problems with availability of HPV vaccines
Human papillomavirus (HPV) vaccines have been difficult to obtain both in Poland and the rest of Europe, as producers cannot keep up with demand, reports Gazeta Wyborcza (p25) in its Tylko Zdrowie supplement on Friday.
Coronavirus has no therapy or vaccine
Coronavirus, the disease that has recently broken out in Wuhan, China, infecting 4,500 people and causing 106 deaths worldwide, has no working therapy or vaccine, while production of such a vaccine would need to last several months, reported Gazeta Wyborcza (p3) on Wednesday and Rzeczpospolita (pA11) on Thursday.
Mabion awaiting registration decision for its rituximab biosimilar
Mabion has sent its replies to the European Medicines Agency on two registration submissions of MabionCD20, a rituximab biosimilar used for treating lymphomas, leukaemia and autoimmune diseases in the registration decision procedure, reported Parkiet Gazeta Giełdy (p05) on Thursday.
The registration submissions include MabionCD20's basic indications and indications without rheumatoid arthritis. The EMA's questions mainly applied to commercial production of the drug, its similarities between the production of the version of MabionCD20 examined, which is used in clinical trials and the reference drug, Rituximab.
OncoArendi qualified for an R&D subsidy
OncoArendi has qualified for a 22 million zloty (€5 million) research and development subsidy from the National Centre for Research and Development (NCBiR) for its experimental cancer treatment, estimated at 31 million zlotys (€7 million) in total, reported Parkiet Gazeta Giełdy (p04) on Thursday.
Biotts expands operation into pharma R&D
Biotts, a biotech start-up specialising in transdermal drug administration technology, has started R&D operations and pre-clinical trials for biosimilars used in neurology and tissue regeneration and are researching into original transdermal cancer medicines and transdermal technologies for type II diabetes therapies, reports Puls Biznesu (p46) on Friday.